Literature DB >> 21890277

A history of depression in women is associated with an altered GABAergic neuroactive steroid profile.

Susan S Girdler1, Monica Lindgren, Patrizia Porcu, David R Rubinow, Jacqueline L Johnson, A Leslie Morrow.   

Abstract

The 3α,5α- and 3α,5β-reduced metabolites of progesterone, deoxycorticosterone, and dehydroepiandrosterone (DHEA) have potent effects on neurotransmission mediated by GABA(A) receptors, and dysregulation of these receptors has been implicated in depression. Using gas chromatography-mass spectrometry, we compared neuroactive steroid concentrations in women with a history of depressive disorders, but who were in full remission at the time of testing (n=11) to never depressed women (n=17) both before and after a challenge with oral micronized progesterone (300 mg). Serum concentrations of the following were obtained: four progesterone-derived GABAergic neuroactive steroids, the precursor pregnenolone, androstenedione-derived neuroactive steroids, and the precursor DHEA. As an index of conversion of progesterone to neuroactive steroids, we also examined ratios of neuroactive steroids to progesterone following the oral progesterone challenge. Results indicated that both before and after oral progesterone, women with histories of depression showed lower concentrations of all GABAergic neuroactive steroids than never depressed women. Those with a history of depression also had lower cortisol concentrations. Because serum neuroactive steroids are mainly synthesized in the adrenals, we hypothesize that histories of depression may be associated with persistent adrenal suppression. Following the progesterone challenge, ratios of the progesterone-derived neuroactive steroids to plasma progesterone concentrations were elevated in women with depression histories, suggesting there may be an adaptive shift in the metabolism of progesterone that compensates for lower circulating neuroactive steroid concentrations. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21890277      PMCID: PMC3233657          DOI: 10.1016/j.psyneuen.2011.08.004

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  57 in total

1.  If it goes up, must it come down? Chronic stress and the hypothalamic-pituitary-adrenocortical axis in humans.

Authors:  Gregory E Miller; Edith Chen; Eric S Zhou
Journal:  Psychol Bull       Date:  2007-01       Impact factor: 17.737

Review 2.  The relevance of neurosteroids to clinical psychiatry: from the laboratory to the bedside.

Authors:  Rael D Strous; Rachel Maayan; Abraham Weizman
Journal:  Eur Neuropsychopharmacol       Date:  2005-10-27       Impact factor: 4.600

Review 3.  Relevance of endogenous 3alpha-reduced neurosteroids to depression and antidepressant action.

Authors:  Veska Uzunova; Luther Sampson; Doncho P Uzunov
Journal:  Psychopharmacology (Berl)       Date:  2005-10-26       Impact factor: 4.530

4.  Acute and chronic stress increase DHEAS concentrations in rhesus monkeys.

Authors:  Nicole Maninger; John P Capitanio; William A Mason; John D Ruys; Sally P Mendoza
Journal:  Psychoneuroendocrinology       Date:  2010-02-12       Impact factor: 4.905

5.  Fluoxetine decreases concentrations of 3 alpha, 5 alpha-tetrahydrodeoxycorticosterone (THDOC) in major depression.

Authors:  A Ströhle; A Pasini; E Romeo; B Hermann; G Spalletta; F di Michele; F Holsboer; R Rupprecht
Journal:  J Psychiatr Res       Date:  2000 May-Jun       Impact factor: 4.791

6.  Simultaneous quantification of GABAergic 3alpha,5alpha/3alpha,5beta neuroactive steroids in human and rat serum.

Authors:  Patrizia Porcu; Todd K O'Buckley; Sarah E Alward; Christine E Marx; Lawrence J Shampine; Susan S Girdler; A Leslie Morrow
Journal:  Steroids       Date:  2009-01-13       Impact factor: 2.668

Review 7.  Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators.

Authors:  Lotta Andréen; Sigrid Nyberg; Sharuh Turkmen; Guido van Wingen; Guillen Fernández; Torbjörn Bäckström
Journal:  Psychoneuroendocrinology       Date:  2009-03-09       Impact factor: 4.905

8.  Neuroactive steroids modulate HPA axis activity and cerebral brain-derived neurotrophic factor (BDNF) protein levels in adult male rats.

Authors:  Gaëlle Naert; Tangui Maurice; Lucia Tapia-Arancibia; Laurent Givalois
Journal:  Psychoneuroendocrinology       Date:  2007-10-24       Impact factor: 4.905

Review 9.  Recent developments in the significance and therapeutic relevance of neuroactive steroids--Introduction to the special issue.

Authors:  A Leslie Morrow
Journal:  Pharmacol Ther       Date:  2007-04-24       Impact factor: 12.310

10.  Pituitary-adrenal and sympathetic nervous system responses to stress in women remitted from recurrent major depression.

Authors:  Thorben Ahrens; Michael Deuschle; Bertram Krumm; Gita van der Pompe; Johan A den Boer; Florian Lederbogen
Journal:  Psychosom Med       Date:  2008-03-31       Impact factor: 4.312

View more
  31 in total

1.  Replication of Epigenetic Postpartum Depression Biomarkers and Variation with Hormone Levels.

Authors:  Lauren Osborne; Makena Clive; Mary Kimmel; Fiona Gispen; Jerry Guintivano; Tori Brown; Olivia Cox; Jennifer Judy; Samantha Meilman; Aviva Braier; Matthias W Beckmann; Johannes Kornhuber; Peter A Fasching; Fernando Goes; Jennifer L Payne; Elisabeth B Binder; Zachary Kaminsky
Journal:  Neuropsychopharmacology       Date:  2015-10-27       Impact factor: 7.853

2.  A stress steroid triggers anxiety via increased expression of α4βδ GABAA receptors in methamphetamine dependence.

Authors:  H Shen; A Mohammad; J Ramroop; S S Smith
Journal:  Neuroscience       Date:  2013-08-29       Impact factor: 3.590

3.  Oxytocin receptor DNA methylation in postpartum depression.

Authors:  Mary Kimmel; Makena Clive; Fiona Gispen; Jerry Guintivano; Tori Brown; Olivia Cox; Matthias W Beckmann; Johannes Kornhuber; Peter A Fasching; Lauren M Osborne; Elisabeth Binder; Jennifer L Payne; Zachary Kaminsky
Journal:  Psychoneuroendocrinology       Date:  2016-04-08       Impact factor: 4.905

Review 4.  Neurosteroid, GABAergic and hypothalamic pituitary adrenal (HPA) axis regulation: what is the current state of knowledge in humans?

Authors:  Shannon K Crowley; Susan S Girdler
Journal:  Psychopharmacology (Berl)       Date:  2014-04-23       Impact factor: 4.530

Review 5.  Neuroactive Steroids and Perinatal Depression: a Review of Recent Literature.

Authors:  Katherine McEvoy; Jennifer L Payne; Lauren M Osborne
Journal:  Curr Psychiatry Rep       Date:  2018-08-09       Impact factor: 5.285

6.  Juvenile social isolation affects maternal care in rats: involvement of allopregnanolone.

Authors:  Maria Giuseppina Pisu; Giorgia Boero; Francesca Biggio; Anna Garau; Daniela Corda; Mauro Congiu; Alessandra Concas; Patrizia Porcu; Mariangela Serra
Journal:  Psychopharmacology (Berl)       Date:  2017-06-16       Impact factor: 4.530

7.  Lower allopregnanolone during pregnancy predicts postpartum depression: An exploratory study.

Authors:  Lauren M Osborne; Fiona Gispen; Abanti Sanyal; Gayane Yenokyan; Samantha Meilman; Jennifer L Payne
Journal:  Psychoneuroendocrinology       Date:  2017-02-16       Impact factor: 4.905

8.  GABAergic neuroactive steroids and resting-state functional connectivity in postpartum depression: a preliminary study.

Authors:  Kristina M Deligiannidis; Elif M Sikoglu; Scott A Shaffer; Blaise Frederick; Abby E Svenson; Andre Kopoyan; Chelsea A Kosma; Anthony J Rothschild; Constance M Moore
Journal:  J Psychiatr Res       Date:  2013-03-15       Impact factor: 4.791

Review 9.  Pregnenolone sulfate as a modulator of synaptic plasticity.

Authors:  Conor C Smith; Terrell T Gibbs; David H Farb
Journal:  Psychopharmacology (Berl)       Date:  2014-07-06       Impact factor: 4.530

10.  Menstrual mood disorders are associated with blunted sympathetic reactivity to stress.

Authors:  Rebecca R Klatzkin; Adomas Bunevicius; Catherine A Forneris; Susan Girdler
Journal:  J Psychosom Res       Date:  2013-11-12       Impact factor: 3.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.